Gosselar et al. analyzed the positive predictive value of DRE in the first three screening rounds at the Rotterdam section of the European Randomised Screening Prostate Cancer trial in 5040 prostate biopsies conducted in men referred due to a serum PSA level of 3.0 ng/mL or higher. This evidence concerns the gene KLK3 and prostate carcinoma.